

■ General Information

Applications

- Immunohistochemistry
 - TUNEL for apoptosis
- In situ hybridization (ISH)
 - mRNA
 - miRNA
 - Fluorescent In situ hybridization (FISH)

Storage and stability

- Individual slide is put in an air-tight pack with inert gas.
- If the slides are stored at 4C, they are good for up to one year.

How processed

- Tissues were initially fixed with formalin except for some of the animal tissues
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Sectioned by microtome in 4 µm thickness

Before use

- Dry slides for 1 hour in a oven at 60C.
- Dewax slides in xylene for 4 minutes x 5 times.
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes.

Slide orientation

- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.

Shaded area	1	2	3	4	5	6	7	8	9	10
	11	12	13	14	15	16	17	18	19	20
	21	22	23	24	25	26	27	28	29	30
	30	32	33	34	35	36	37	38	39	40
	41	42	43	44	45	46	47	48	49	50
	51	52	53	54	55	56	57	58	59	60

■ Tissue types*

The "tissue type" column in the data sheet denotes the following categories.

1. normal tissue from a non-cancer patient
2. normal tissue from a cancer patient, but the cancer involves unrelated organ
3. normal tissue adjacent to the cancer
4. benign tumor
5. tumor of borderline malignancy or uncertain malignant potential
6. cancer

NBP2-30212 - Human Breast Tissue MicroArray (Cancer)

No.	Age	Sex	Organ	Diagnosis	pTNM	Stage	LN*	Tissue type **
1	59	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/19	6
2	48	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/16	6
3	42	F	Breast	infiltrating duct carcinoma	T2N2aM0	IIIA	5/19	6
4	37	F	Breast	infiltrating duct carcinoma	T2N2aM0	IIIA	8/8	6
5	37	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/20	6
6	55	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/19	6
7	55	F	Breast	infiltrating duct carcinoma	T3N3aM0	IIIC	20/20	6
8	36	F	Breast	infiltrating duct carcinoma	T3N0M0	IIB	0/14	6
9	52	F	Breast	infiltrating duct carcinoma	T2N2aM0	IIIA	5/24	6
10	40	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/11	6
11	51	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/8	6
12	55	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/19	6
13	60	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/16	6
14	45	F	Breast	sarcomatoid carcinoma	T2N1aM0	IIB	3/23	6
15	38	F	Breast	infiltrating duct carcinoma	T3N1aM0	IIIA	3/13	6
16	53	F	Breast	infiltrating duct carcinoma	T2N1miM0	IIB	3/14	6
17	48	F	Breast	infiltrating duct carcinoma	T2N1miM0	IIB	2/15	6
18	37	F	Breast	infiltrating duct carcinoma	T2N1b	IIB	3/18	6
19	40	F	Breast	infiltrating duct carcinoma	T3N0M0	IIB	0/10	6
20	28	F	Breast	infiltrating lobular carcinoma	T3N0M0	IIB	0/20	6
21	56	F	Breast	infiltrating duct carcinoma	T2N0M0	IIA	0/14	6
22	45	F	Breast	metaplastic carcinoma	T2N0M0	IIA	0/17	6
23	42	F	Breast	infiltrating duct carcinoma	T2N3aM0	IIIC	12/26	6
24	47	F	Breast	infiltrating duct carcinoma	T2N1miM0	IIB	1/11	6
25	51	F	Breast	infiltrating duct carcinoma	T4N1bM0	IIIB	6/10	6
26	51	F	Breast	infiltrating duct carcinoma	T2N1aM0	IIB	1/13	6
27	57	F	Breast	infiltrating duct carcinoma	T2N1bM0	IIB	1/10	6
28	57	F	Breast	infiltrating duct carcinoma	T3N1aM0	IIIA	3/7	6
29	52	F	Breast	infiltrating duct carcinoma	T2N1aM0	IIB	1/22	6
30	41	F	Breast	infiltrating duct carcinoma	T3N2aM0	IIIA	7/9	6
31	48	F	Breast	infiltrating duct carcinoma	T2N3aM0	IIIC	35/35	6
32	34	F	Breast	infiltrating duct carcinoma	T2N1aM0	IIB	2/11	6
33	37	F	Breast	infiltrating duct carcinoma	T2N3aM0	IIIC	22/23	6
34	58	F	Breast	infiltrating duct carcinoma	T2N3aM0	IIIC	19/22	6
35	37	F	Breast	infiltrating duct carcinoma	T2N3aM0	IIIC	17/19	6
36	66	F	Breast	infiltrating duct carcinoma	T2N2aM0	IIIA	4/11	6
37	51	F	Breast	infiltrating duct carcinoma	T2N1aM0	IIB	3/16	6
38	41	F	Breast	infiltrating duct carcinoma	T2N3aM0	IIIC	15/21	6
39	56	F	Breast	infiltrating duct carcinoma	T3N2aM0	IIIA	5/13	6
40	47	F	Breast	infiltrating duct carcinoma	T3N3aM0	IIIC	11/13	6
41	48	F	Lymph node	metastatic carcinoma from #31	.	.	.	6
42	34	F	Lymph node	metastatic carcinoma from #32	.	.	.	6
43	37	F	Lymph node	metastatic carcinoma from #33	.	.	.	6
44	58	F	Lymph node	metastatic carcinoma from #34	.	.	.	6
45	37	F	Lymph node	metastatic carcinoma from #35	.	.	.	6
46	66	F	Lymph node	metastatic carcinoma from #36	.	.	.	6
47	51	F	Lymph node	metastatic carcinoma from #37	.	.	.	6
48	41	F	Lymph node	metastatic carcinoma from #38	.	.	.	6
49	56	F	Lymph node	metastatic carcinoma from #39	.	.	.	6
50	47	F	Lymph node	metastatic carcinoma from #40	.	.	.	6
51	37	F	Breast	normal (match to #5)	.	.	.	3
52	48	F	Breast	normal (match to #31)	.	.	.	3
53	36	F	Breast	normal (match to #8)	.	.	.	3
54	40	F	Breast	normal (match to #10)	.	.	.	3
55	51	F	Breast	normal (match to #11)	.	.	.	3
56	55	F	Breast	normal (match to #12)	.	.	.	3
57	60	F	Breast	normal (match to #13)	.	.	.	3
58	58	F	Breast	normal (match to #34)	.	.	.	3
59	37	F	Breast	normal (match to #35)	.	.	.	3
60	.	.	Carbon

TNM and stage : AJCC Cancer Staging Manual (7th Edition)

* LN, positive lymph nodes / examined lymph nodes

51-60: Non-neoplastic breast tissue in breast cancer patients.